SC issues notices to Centre, others on Novartis petition

Posted on: Mon, 02 Nov 2009 21:45:00 EST


Symbols: NAPHF
New Delhi, Sep 11, 2009 (Asia Pulse Data Source via COMTEX) --
NAPHF | Quote | Chart | News | PowerRating -- The Supreme Court of India Friday issued notices to Indian government, pharma major Cipla, Ranbaxy Lab, Hetero Drugs, Natco Pharma and others on a pettion filed by Swiss firm Novartis AG challenging the denial of patent for its blood cancer drug Glivec in beta crystal form.

A Bench headed by Justice Dalveer Bhandari sought replies from the Ministry of Industry and Commerce, the Comptroller General of Patent and Design, the Cancer Patient Aid Association and the four pharma companies.

The Intellectual Property Appellate Board (IPAB) in July rejected Novartis' appeal against a Chennai patent office's decision to deny patent.

The patent was denied based on several grounds, including Sections 3(d) and 3(b) of the Indian Patent Law.

Section 3(d) of the Patent Law restricts patents for already known drugs unless the new claims are superior in terms of efficacy. Section 3(b) restricts patents for products that are against public interest and do not demonstrate enhanced efficacy over existing products.

Novartis had obtained an exclusive marketing right (generic versions of Glivec were stopped from being made) in 2003 for the drug based on its patent application.

For full details on (NAPHF) NAPHF. (NAPHF) has Short Term PowerRatings at TradingMarkets. Details on (NAPHF) Short Term PowerRatings is available at This Link.

UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday February 11 04:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.